新诊断急性髓系白血病不同治疗亚组中RAS突变状态的意义
该研究纳入1410例新诊断急性髓系白血病患者,RAS突变见于273例(20%)。RAS突变组3年生存率38%,RAS野生型组28%(p=.01)。在RAS突变患者中,有利核型、伴NPM1突变及接受强化化疗与较高缓解率相关,继发性及治疗相关继发性AML与低缓解率相关。
要点
- 新诊断AML中RAS突变率为20%(273/1410)。
- RAS突变组3年生存率38%,高于RAS野生型组的28%(p=.01)。
- RAS突变患者中,强化化疗与高缓解率相关(OR 5.9)。
核心结论
- RAS突变在新诊断AML中占20%,RAS突变患者3年生存率38% vs RAS野生型28%(p=.01)。
- 在RAS突变患者中,有利核型、伴NPM1突变及强化化疗与较高缓解率相关,继发性及治疗相关继发性AML与低缓解率相关。
研究设计与样本
- 研究纳入1410例新诊断急性髓系白血病患者,分析RAS突变状态与不同治疗亚组的特征及结局。
主要发现
- RAS突变见于273例(20%)患者。
- RAS突变组3年生存率38% vs RAS野生型组28%(p=.01)。
- RAS突变患者中,有利核型与较高CR/CRi率相关,OR 23.2(95%CI:2.7-192.7;p<.001)。
- RAS突变患者中,伴NPM1突变与较高CR/CRi率相关,OR 2.8(95%CI:1.1-6.9;p=.02)。
- RAS突变患者中,继发性AML与低缓解率相关,OR 0.34(95%CI:0.1-0.9;p=.04);治疗相关继发性AML与低缓解率相关,OR 0.22(95%CI:0.09-0.5;p=.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activating mutations in RAS have been reported in about 10-15% of patients with AML; previous studies have not identified a prognostic significance. However, RAS mutations have emerged as a potential resistance mechanism to treatment with inhibitors of FLT3, IDH, and BCL2. We aimed to determine the characteristics and outcomes of patients with RAS-mutated (RAS-mut) AML across therapy subsets of 1410 patients newly diagnosed (ND AML). RAS-mut was observed in 273 (20%) patients. Overall, patients with RAS-mut AML had an estimated 3-year survival rate of 38% vs. 28% in those with RAS wild type (RAS-wt), p = .01. Among patients with RAS-mut, favorable karyotype and concomitant NPM1 mutations were associated with a higher CR/CRi rate, OR 23.2 (95% CI: 2.7-192.7; p < .001) and OR 2.8 (95% CI: 1.1-6.9; p = .02), respectively, while secondary and treated secondary (ts)-AML were associated with low response rates, OR 0.34 (95% CI: 0.1-0.9; p = .04) and OR 0.22 (95% CI: 0.09-0.5; p = .001), respectively. Intensive chemotherapy was associated with high response rates OR 5.9 (95% CI: 2.9-12.2; p < .001). Better median OS was observed among those with favorable karyotype, HR 0.28 (95% CI: 0.1-0.6; p = .002), and those treated with intensive chemotherapy, HR 0.42 (95% CI: 0.2-0.6 p < .001). Conversely, ts- AML and co-occurrence of mutations in TP53 were associated with poor median OS; HR 2.3 (95% CI: 1.4-3.9; p = .001) and HR 1.7 (95% CI: 0.9-3.1; p = .06), respectively. The addition of venetoclax was associated with a non-significant improvement in CR/CRi and OS.
引用
- Rivera D, Kim K, Kanagal-Shamanna R, et al. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022. PMID: 36117258. doi:10.1002/ajh.26731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。